Table 3.
Summary of the drugs inhibiting antiapoptotic pathways.
| Drug | Mechanism of action | Route of administration | Common side effects | Reference or clinicaltrials.gov identifier |
|---|---|---|---|---|
| Idasanutlin | inhibiting the formation of the P-53-MDM2 complex | IV | Diarrhea, loss of appetite, bleeding problems | NCT02670044 |
| NCT04029688 | ||||
| Milademetan | Inhibits MDM-2 | orally | Nausea, loss of appetite, platelet count decreased, fatigue, anemia | NCT03671564 |
| NCT03552029 | ||||
| Oblimersen | BCL2 antisense oligonucleotide | Continuous IV infusion | Nausea, thrombocytopenia, pyrexia, fatigue, anemia, vomiting | NCT00085124 |
| Obatoclax mesylate | BH3 mimetic Binding to the BH3-binding site of BCL2, BCL2L1, BCL-W, BCL-B, MCL1, and A1 |
IV infusion | Neutropenia, thrombocytopenia, anemia, bleeding, fatigue | NCT00684918 |
| NCT01150656 | ||||
| NCT00438178 | ||||
| Venetoclax (FDA approved) | BH3 mimetic Inhibiting BCL2 and BCL-W |
orally | Nausea, diarrhea, anemia, upper respiratory infection, thrombocytopenia, fatigue | NCT03987958 |
| NCT02265731 | ||||
| NCT03844048 | ||||
| NCT03123029 | ||||
| S64315 | MCL1 inhibitor | IV infusion | Tumor lysis syndrome, heart injury, fever | NCT03672695 |
| Sorafenib | Inhibiting MCL1 translocation | orally | Bleeding gums, blood in urine or stools, coughing blood, redness of the hands, difficulty with breathing | NCT00516828 |